Global Gout Drug Market Revenue, Industry Growing Demand, Size, Share and Forecast – 2028

The global gout drug market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). Gout is a type of arthritis that occurs when the body develops extra uric acid. This leads to the formation of sharp crystals which may develop in the toe or any joints of the body. As per health experts, this causes swelling and pain in that part of the joint and is known as gout attack. It can be treated by changes in lifestyle and with proper medication. Some arthritis cause inflammation in joint and muscles. Inflammation occurs in gout is a form of inflammatory arthritis. Gout inflammation is usually there in the big toe part, however, they are also found in the knee, ankle, foot, wrist, and elbow. This condition can happen to anyone, however, is more common in men than women. After menopause occurs in women, they are affected by gout. Due to higher levels of uric acid, men are more likely to be affected by gout. In women, uric acid levels are on the rise after they reach menopause. Nonsteroidal inflammatory drugs, Colchicine, and corticosteroids are some medications that are used for gout treatment.

Clinical developments by pharmaceutical companies are expected to drive the market during the forecast period. For instance, in June 2021, a gout treatment drug on which Arrowhead Pharmaceuticals was researching will further be developed by the partnership with Horizon Therapeutics. As per the agreement, Horizon Therapeutics will be paying $40 million for acquiring the global rights to the drug. The agreement further entails all the preclinical research of the drug to Arrowhead Pharmaceuticals and Horizon Therapeutics will look after the clinical development of the drug. The company will also be responsible for the commercialization of the medicine once it is approved by the respective agency. Arrowhead therapeutics could earn up to $660 million from royalty. This drug is developed by using RNA interference. RNA interference is a mechanism that stops a gene that is producing a disease-causing protein in the body. The mechanism of stopping a gene from producing disease-causing protein is known as gene silencing. The arrow head is developing this drug in a way that its effect lasts for a long period.

Some major players in the market include GlaxoSmithKline plc, Merck & Co., Inc., and Takeda Pharmaceutical Co., Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2020, an agreement was made between Swedish Orphan Biovitrum AB and Selecta Biosciences, Inc. to develop a drug that would be efficient in the treatment of chronic refractory gout. This drug is SEL-212 and it reduces the level of uric acid in the body. SEL-212 is developed by Selecta’s tolerogenic ImmTOR immune tolerance platform. In this agreement, Sobi is will further make more advancements to SEL-212 by development and commercialization.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Class
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- GlaxoSmithKline plc, Merck & Co., Inc., and Takeda Pharmaceutical Co., Ltd, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gout Drug Market Report by Segment

By Drug Class

• Colchicine
• Antihyperuricemic Agents
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Biologic Response Modifiers
• Others

By Application

• Acute Gout
• Chronic Gout

Global Gout Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa